載入...
Chimeric Antigen Receptor T cells for Multiple Myeloma: The Journey So Far – And the Road Ahead
Despite improvements in effective therapy, multiple myeloma remains incurable and virtually all patients will face relapsed disease at some point after diagnosis. The prognosis for relapsed myeloma after developing resistance to anti-CD38 monoclonal antibodies, proteasome inhibitors, immunomodulator...
Na minha lista:
| 發表在: | Cancer J |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7988823/ https://ncbi.nlm.nih.gov/pubmed/33750070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000506 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|